Black Diamond Therapeutics Stock Rises 11% After Q1 Results
Black Diamond Therapeutics (BDTX) shares gained 11% in a week following the release of its Q1 results. The company reported lower costs, a cash runway extending into 2028, and continued progress for its lead candidate silevertinib. The stock rise reflects investor optimism about the company's financial stability and drug development pipeline.
Key facts
- BDTX shares gained 11% in a week.
- Q1 results showed lower costs.
- Cash runway extends into 2028.
- Lead candidate silevertinib continues to progress.
- Stock rise reflects investor optimism.
- Black Diamond Therapeutics is the company.
- Silevertinib is the lead drug candidate.
- Financial stability and pipeline progress drove gains.
Entities
Institutions
- Black Diamond Therapeutics
Sources
- Quartz —